TORONTO, Jan. 12, 2015 — MaRS Innovation, the commercialization agent for Ontario's 15 leading academic institutions, today announced that it has formed a research collaboration with Johnson & Johnson Innovation, LLC and its Canadian affiliate, Janssen Inc., to advance three technologies focused on cardiac, diabetes and depression, respectively.
This announcement was covered in Lab Product News.
"These three projects reflect the quality of innovation present in Toronto's research community for our industry partners, and Toronto's progress in addressing healthcare issues of international concern," ...
January 12, 2015
in Centre for Addiction and Mental Health (CAMH), Funding or Fundraising-Announcements, Industry Partners, Licenseable Technologies, Member Institutions, News, Partnerships, Portfolio, University Health Network, University of Toronto
Here's a snapshot of some recent portfolio activity:
UTEST, the early-stage technology accelerator MI runs in partnership with the University of Toronto, was cited in the Wall Street Journal as part of what makes Toronto the best place to build a start-up in Canada and the eighth-best place in the world. Applications for UTEST's the third cohort are open until Thursday, April 17, 2014.
OtoSim Inc. placed first out of 20 companies in the Venture Pitch competition at the Fundica Funding Roadshow for ...
April 14, 2014
in Awards, Licenseable Technologies, Media Coverage, Member Institutions, News, OtoSim Inc., Portfolio, Start-Up Companies, University of Toronto, UTEST Program
Technology developed by Dr. Stuart Berger at UHN is first project funded through partnership
TORONTO, Dec. 11, 2013 - MaRS Innovation, a Centre of Excellence for Commercialization and Research, has announced the first project funded through the Pfizer Inc. and MaRS Innovation strategic partnership.
Dr. Stuart Berger, senior scientist at University Health Network, has developed a potential innovation for the bio-manufacturing sector, which is a rapid-growth area.
This announcement was covered by BetaKit.
His technology generates cell lines with improved protein production and survival properties, important in the ...
Mount Sinai’s Lunenfeld-Tanenbaum Research Institute has developed a new test that could make a big difference to men facing infertility.
A study published in a leading international journal, Science Translational Medicine, details the discovery of a key biomarker that can pinpoint the cause of infertility without the need for invasive surgery.
This story was covered by BBC News, ABC News's "PM" with Mark Colvin, CTV News, CBC News, The Toronto Star, Globe and Mail, Ottawa Citizen and the Calgary Herald.
About half a million ...
Over 340 people worldwide have joined WaveCheck's Indiegogo crowdfunding campaign to fund a breakthrough clinical technique for breast cancer that promises to revolutionize the way chemotherapy is monitored.
"Breast Cancer Awareness Month’s positivity makes it easy to overlook the fact that 60 to 70 per cent of chemotherapy treatments fail,” says Dr. Gregory Czarnota, chief of Radiation Oncology at Sunnybrook Health Sciences Centre and co-inventor of WaveCheck with Professor Michael C. Kolios of Ryerson University. “WaveCheck’s technology can tell people with breast ...
November 5, 2013
in Funding or Fundraising-Announcements, International Projects, Licenseable Technologies, Media Coverage, Member Institutions, News, Portfolio, Ryerson University, Sunnybrook Health Sciences Centre, WaveCheck
Indiegogo campaign to raise funds for North American clinical study during Breast Cancer Awareness Month; 12 artists donate 13 original works worth over $15,000 to support campaign
Toronto, Canada (October 9, 2013) — WaveCheck — a painless, non-surgical clinical technique developed by a Sunnybrook Health Sciences Centre oncologist and a Ryerson University physicist and supported by MaRS Innovation — is poised to transform chemotherapy response monitoring for women with breast cancer.
WaveCheck combines traditional ultrasound with new software to detect responses to chemotherapy in breast cancer ...
October 9, 2013
in Licenseable Technologies, Media Coverage, Member Institutions, News, Portfolio, Ryerson University, Sunnybrook Health Sciences Centre, University of Toronto, Video, WaveCheck
Stem Cell Therapeutics Corp. (TSX-V: SSS), a biopharmaceutical company developing cancer stem cell-related technologies, has signed a definitive license agreement with University Health Network (UHN), Toronto, Canada.
The agreement, developed in collaboration with MaRS Innovation, provides Stem Cell Therapeutics (SCT) with exclusive worldwide rights to an innovative clinical cancer stem cell program.
This announcement builds upon the existing stem cell program agreement between MI, Stem Cell Therapeutics and UHN, which was announced in November 2012.
The initial consideration of $1.6 million for the UHN ...
Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. You can read the original post on the MaRS blog.
Created in 2008, MaRS Innovation (MI) bridges the chasm between the early-stage technologies emerging from its 16 member institutions and successful startup companies and licensable technologies.
By offering early-stage funding in tandem with hands-on management, business development, mentorship and intellectual property protection strategy, MI acts as ...
March 26, 2013
in Baycrest Centre for Geriatric Care, Centre for Addiction and Mental Health (CAMH), Funding or Fundraising-Announcements, Government Partners, Holland Bloorview Kids Rehabilitation Hospital, Licenseable Technologies, MaRS Discovery District, Member Institutions, News, Partnerships, Portfolio, Ryerson University, Sinai Health, St. Michael's Hospital, Start-Up Companies, Sunnybrook Health Sciences Centre, The Hospital for Sick Children (SickKids), The Ontario Institute for Cancer Research (OICR), Thunder Bay Regional Research Institute (TBRRI), TIAP Staff, University Health Network, University of Toronto, Women's College Hospital, York University
Networks of Centres of Excellence recognizes strength of partnership between MI and its 16 member institutions
TORONTO, February 5, 2013 — How do you make sure the brilliant ideas emerging from Toronto’s academic research community get the best possible chance to succeed?
MaRS Innovation (MI), created in 2008, bridges the chasm between these early-stage technologies and successful start-up companies and licensable technologies. By offering early-stage funding in tandem with hands-on management, mentorship and IP strategy protection, MI acts as a commercialization agent for ...
February 6, 2013
in Awards, Baycrest Centre for Geriatric Care, Centre for Addiction and Mental Health (CAMH), Funding or Fundraising-Announcements, Government Partners, Holland Bloorview Kids Rehabilitation Hospital, Industry Partners, Licenseable Technologies, MaRS Discovery District, Member Institutions, News, Partnerships, Portfolio, Ryerson University, Sinai Health, St. Michael's Hospital, Start-Up Companies, Sunnybrook Health Sciences Centre, The Hospital for Sick Children (SickKids), The Ontario Institute for Cancer Research (OICR), Thunder Bay Regional Research Institute (TBRRI), TIAP Staff, University Health Network, University of Toronto, Women's College Hospital, York University
An early-stage technology that may revolutionize the way burn victims are treated is generating considerable buzz in Toronto media this week.
Globe and Mail reporter Robert Everett-Green wrote about the joint University of Toronto and Sunnybrook Health Sciences Centre project January 20 in "A 3-D machine that prints skin? How burn care could be revolutionized."
Health reporter Beatrice Politi also covered the Bio Printer project for Global News Toronto January 21. Her video segment includes an interview with PhD student Lian Leng and ...